TY - JOUR T1 - Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study JF - medRxiv DO - 10.1101/2020.03.28.20045955 SP - 2020.03.28.20045955 AU - Lichao Fan AU - Huan Liu AU - Na Li AU - Chang Liu AU - Ye Gu AU - Yongyu Liu AU - Yu Chen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/30/2020.03.28.20045955.abstract N2 - Background COVID-19 is an emerging disease caused by the SARS-CoV-2 virus; no specific medication has been identified to date. We aimed to investigate the administered medications and intervention times for patients who completely recovered from COVID-19.Methods This single-center, retrospective, and observational study included 55 patients with COVID-19 who were transferred to Shenyang Sixth People’s Hospital between January 20 and March 15, 2020. Demographic information, symptoms, laboratory indicators, treatment processes, and clinical outcomes were collected. Administered drugs and intervention times were compared in 47 and eight patients with mild and severe symptoms, respectively.Findings All 55 patients recovered. Fifty-three patients (96·36%) received antiviral therapy, including 45 in the mild group (median treatment: 14 days; 17 received umifenovir) and all eight severe-group patients (median treatment: 17·5 days; four received lopinavir/ritonavir). Twenty-nine patients (52·72%) were administered antibiotics, including 21 in the mild group (median treatment: 13·5 days; 15 received moxifloxacin) and all eight in the severe group (median treatment: 9 days; two received linezolid). Moreover, seven patients (12·72%) were treated with glucocorticoids and nine (16·36%) with immunomodulators.Interpretation Given the 100% recovery rate, early administration of antiviral drugs can be considered. Umifenovir may benefit patients with mild symptoms, while lopinavir/ritonavir may benefit those with severe symptoms. Prophylactic administration of common antibiotics may reduce the risk of co-infection. The use of glucocorticoids is usually not necessary.Funding This work was supported by the Shenyang Major Science and Technology Innovation R&D Program (JY2020-9-018 to Y. Chen).Competing Interest StatementThe authors have declared no competing interest.Funding Statement This work was supported by the Shenyang Major Science and Technology Innovation R&D Program (JY2020-9-018 to Y. Chen).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request. ER -